Progress in pathogenesis and therapy of vasculitis syndrome

• ORIGUCHI Tomoki

  Graduate School of Health Sciences, Nagasaki University First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University

• ICHINOSE Kunihiro

  First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University

• TAMAI Mami

  First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University

• NAKAMURA Hideki

  First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University

• KAWAKAMI Atsushi

  First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University

• EGUCHI Katsumi

  First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University

Bibliographic Information

Other Title

• ＡＮＣＡ関連血管炎の病態と治療における最近の知見

Abstract

  Since antineutrophil cytoplasmic autoantibody (ANCA) was found, the researches in the pathogenesis of vasculitis syndrome have been developing. Proinflammatory cytokines including tumor necrosis factor-α are induced by certain infections, by which ANCA that binds to granule components of cytoplasm adhesions to endothelial cells. These endothelial cells produce proteolytic enzymes and oxygen radicals, which leads to vasculitis. It might be contributed in the production of ANCA that bacterial organisms are mimicry to the peptide sequences of granule components. The multicentric randomized clinical trials undertaken by the European Vasculitis Study Group (EUVAS) optimized that cyclophosphamide-corticosteroid combination therapy was useful to ANCA-associated vasculitis. It is increasing evidences that biologics are useful to ANCA-associated vasculitis, although it is necessary to take care of severe adverse effects.<br>

Journal

• Japanese Journal of Clinical Immunology

  Japanese Journal of Clinical Immunology 30 (6), 432-443, 2007

  The Japan Society for Clinical Immunology

Keywords

• Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis
• tumor necrosis factor (TNF)-α
• infliximab
• etanercept
• rituximab

Details

• CRID: 1390282679627872768
• NII Article ID: 10021241958
• NII Book ID: AN00357971
• DOI: 10.2177/jsci.30.432
• ISSN: 13497413
• ISSN: 09114300
• HANDLE: 10069/23602
• PubMed: 18174672
• Web Site: https://nagasaki-u.repo.nii.ac.jp/records/15673
• Web Site: http://www.jstage.jst.go.jp/article/jsci/30/6/30_6_432/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2008107789
• Text Lang: ja
• Data Source:
  • JaLC
  • IRDB
  • Crossref
  • PubMed
  • CiNii Articles
• Abstract License Flag: Disallowed